
Chemical Science

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



The specificity of thioredoxins and glutaredoxins is determined by electrostatic and geometric complementarity

Carsten Berndt¹, Jens-Dirk Schwenn², and Christopher Horst Lillig³#

From the Department of Neurology, Medical Faculty, Heinrich-Heine Universität, Merowingerplatz 1a, 40225 Düsseldorf, Germany (1), Biochemistry of Plants, Ruhr-Universität Bochum, Universitätsstraße 150, 44780 Bochum, Germany (2), and the Institute for Medical Biochemistry and Molecular Biology, Universitätsmedizin Greifswald, Ernst-Moritz-Arndt Universität, Ferdinand Sauerbruch Straße, 17475 Greifswald, Germany (3).

Address for correspondence: Christopher Horst Lillig, Institute for Medical Biochemistry and Molecular Biology, Universitätsmedizin Greifswald, Ferdinand Sauerbruch Straße, DE-17475 Greifswald, Germany; tel.: +49-3834 86 5407; fax: +49-3834 8605402; e-mail: horst@lillig.de Keywords: glutaredoxin, thioredoxin, electrostatic interactions, redox potential

Table of contents entry



Specific long- and short-range electrostatic interactions and not redox potentials determine the substrate specificity of Trx family proteins.

Abstract

The thiol-disulfide oxidoreductases from the thioredoxin (Trx) family of proteins have a broad range of well documented functions and possess distinct substrate specificities. The mechanisms and characteristics that control these specificities are key to the understanding of both the reduction of catalytic disulfides as well as allosteric disulfides (thiol switches). Here, we have used the catalytic disulfide of $E.\ coli\ 3'$ -phosphoadenosine 5'-phosphosulfate (PAPS) reductase (PR), that forms between the single active site thiols of two monomers during the reaction cycle, as a model system to investigate the mechanisms of Trx and Grx protein specificity. Enzyme kinetics, $\Delta E^{0'}$ determination, and structural analysis of various Trx and Grx family members suggested: The redox potential does not determine specificity nor efficiency of the redoxins as reductant for PR. Instead, the efficiency of PR with various redoxins correlated strongly to the extend of a negative electric field of the redoxins reaching into the solvent outside the active site, and electrostatic and geometric complementary contact surfaces. These data suggest that, in contrast to common assumption, the composition of the active site motif is less important for substrate specificity than other amino acids in or even outside the immediate contact area.

Introduction

During the past decade the concept of cellular redox homeostasis more and more shifted from the idea of a redox balance between oxidants and antioxidants towards the concept of spatio-temporally controlled redox signalling events. These events are specific with respect to the cysteinyl residues modified and the redox compounds and enzymes involved. Thioredoxins (Trxs) and glutaredoxins (Grxs) are the master regulators of the redox state of the thiol groups of the proteome with numerous well documented functions in essentially all cellular processes, including metabolism and cell signalling, see for instance ^{1 2 3 4}. In most cases, Trxs and Grxs reduce catalytic and allosteric disulfides, a classification introduced by Hogg and coworkers ⁵. Although Trxs and Grxs have a broad range of functions, each member of the family has distinct substrate specificities. The mechanisms and characteristics that control these specificities are unclear and were hardly addressed before.

Both Trxs and Grxs are part of the Trx family of proteins, characterized by a common structure, the Trx fold 6 7. This fold is defined by a central four to five-stranded β -sheet, surrounded by three to four α -helices. Trxs and Grxs catalyze thiol-disulfide exchange reactions. Two thiols in the characteristic Cys-X-X-Cys active site reduced a target disulfide in a reversible two-step reaction. The more N-terminal thiolate cysteinyl residue, located at the surface of the protein in a loop connecting β 1 and α 1 (in Grxs) or β 2 and α 2 (in Trxs), attacks the target disulfide resulting in an intermediate mixed disulfide between the redoxin and the target protein. This is directly attacked by the more C-terminal active site thiol, normally buried in the protein at the beginning of the α -helix (1 or 2), yielding a disulfide in the active site and a reduced target protein. Oxidized Trx is reduced by a Trx reductase and Grx by two molecules of glutathione. This reaction sequence was named the dithiol mechanism to distinguish it from the monothiol mechanism. The latter is used by Grxs to reduce protein-glutathione mixed disulfides and requires only one, the more N-terminal, active site cysteinyl residue.

Both Trxs and Grxs were originally identified as electron donors for ribonucleotide reductase from E. coli 8 9. The requirement for Trx in sulfate assimilation was originally described by Gonzalz-Porqué et al. 10 for yeast. Reduction of sulfate to sulfite requires two electrons with a ΔE_0 of -517 mV. Adenylation and phosphorylation to 3'-phosphoadenonsine-5'-phosphosulfate (PAPS) lowers this redox potential to -60 mV. In E. coli, Trx1 and Grx1 were identified to be the alternative electron donors for the catalytic disulfide in PAPS reductase (PR) 11 12. Enzymatically active PR (EC 1.8.99.4) forms a homo-dimer (2 x 28 kDa). It is devoid of redox-active chromophores but contains a single cysteine in a strictly conserved ECGLH motif that is located at the C-terminus ¹³. Steady state analysis of the reaction and mutagenesis analyses demonstrated that PR follows a ping-pong mechanism in the reduction of PAPS to sulfite and 3'-5'-adenosine diphosphate (PAP) 14 13 15 16 17. In the first step, the PR dimer reduces PAPS directly to sulfite without any detectable sulfate or sulfitebound intermediates. Oxidation of PR yields an intermolecular disulfide between the ECGLH cysteinyl residues of the two monomers. In the second step, this disulfide is the substrate for Trx or Grx and requires the dithiol reaction mechanism of the redoxins for reduction. Although E. coli PR is a rather promiscuous enzyme regarding its choice of electron donors, it cannot be reduced by any Trx or Grx. The high cross-reactivity of E. coli PR was, for instance, useful in the identification and purification of heterologous Trxs from spinach, Synechococcus, and yeast 18. However, the two additional dithiol Grxs of E. coli itself, Grx2 and Grx3 19, cannot reduce PR, neither in vivo 20 nor in vitro 16.

In this study, we have used *E. coli* PR as a model for the analysis of the specificity of Trx family proteins addressing two hypotheses. First, is the functionality of the redoxins determined by the redox potential of their active site dithiol-disulfide redox pair? Or, second, is their functionality determined by specific molecular interactions next to the thiol-disulfide exchange reaction?

Results

Homologous and heterologous thioredoxins and glutaredoxins as electron donors for PAPS reductase

The functionality of various thioredoxins and glutaredoxins from different species with *E. coli* PR was analyzed in kinetic assays. In addition to the well established *E. coli* Trx1 and Grx1, that are regarded to as the physiological reductants ¹² ¹⁶, and the non-active *E. coli* Trx2, Grx2, and Grx3 ¹⁶, we analyzed *E. coli* Grx4 ²¹ and NrdH ²², T4 Grx ²³, *Arabidopsis thaliana* TrxH1, 2, 3, and 4 ²⁴, poplar Grx ²⁵, and human Trx1 ²⁶ and Grx2 ²⁷ ²⁸. The results are summarized in Table 1.

Not surprisingly, *E. coli* Grx4 could not reduce PR. Grx4 is a monothiol-type Grx and the reduction of PR requires the dithiol mechanisms ¹⁶. NrdH, a protein with a Grx-like structure, but Trx-like activity profile is a specific electron donor for the alternative ribonucleotide reductase NrdEF ²², but NrdH is not functional with PR. Grx (formerly Trx) from the bacteriophage T4 was also not able to catalytically reduce PR. In contrast, the four plant Trxs H1-H4 and the plant Grx ²⁵ were able to supply PR with electrons yielding catalytic efficiencies between 18 and 154% compared to *E. coli* Trx1. With human Trx1, PR yielded a catalytic efficiency of 59 %. Human Grx2, on the other hand was not able to reduce the enzyme's catalytic disulfide.

Redox potential of PR

One possible explanation that was suggested why some redoxins are functional in this assay, while others are not, are different standard redox potentials of the dithiol-disulfide pairs of the redoxins. From the literature, the E⁰ of some of the functional redoxins is in the range of -233 to -270 mV, the E⁰ of some of the non-functional redoxins in the range of -198 to -248.5 mV, see Table 1. Although these values did not clearly discriminate the two groups, we decided to determine the redox potential of the active site ECGLH cysteinyl / intermolecular disulfide pair of dimeric PR.

The ping-pong uni-bi-bi reaction sequence of dimeric PR requires a considerable conformational change of the protein during each reaction cycle ¹⁵ ¹⁶ ¹⁷. This conformational change causes small changes in absorbance of the protein in the UV spectrum ¹⁵. These changes were analyzed by difference absorption

spectroscopy using a two beam setup with in series tandem cuvettes in each beam. PR was oxidized by incubation with the substrate PAPS and subsequent removal of the reaction products SO_4^- and PAP by gel filtration chromatography. This oxidation yielded exclusively intermolecular disulfides between two PR monomers (not shown). The reaction mechanism proposed by 29 , involving a stable sulfate-bound intermediate, can be excluded since incubation of reduced PAPS reductase with [^{35}S]-PAPS (in the absence of reductants) yielded no detectable radioactivity associated with the enzyme, confirming earlier conclusions from kinetic experiments 18 15 16 .

In the photometer, the reference beam contained PR (fully oxidized) and a glutathione redox buffer in separate cuvettes, in the sample beam the protein was in the same cuvette as the redox buffer. The glutathione redox buffer also contained a catalytic amount of Grx1 in a ratio of 1:100 to PR. Reduction of PR led to a decrease in absorbance at 253 and 294 nm (Fig. 1A, spectrum 1), likely caused by disulfide reduction and changes in the interactions of a tryptophanyl residue with the solvent. The differences in absorbtion coefficient at 294 nm were recorded over time after incubation in defined glutathione redox buffers until equilibrium was reached, *i.e.* up to seven hours (not shown). The ratio of reduced versus oxidized PR was plotted against the redox potential defined by the redox buffer (Fig. 1B). Non linear regression of 25 independent measurements against the Nernst equation yielded a redox potential of -162.2 mV. This potential is still 36 mV above the potential of Grx3, the non-functional redoxin with the highest potential (-198 mV) ³⁰ and does not correlate to the different activities of the redoxins towards PR, see Table 1.

Structural analysis

What else, if not the redox potential, could determine the different specificities of the Trx family proteins for a rather promiscuous protein like PR? Chartron *et al.* presented a structure of a complex between a monomer of PR and an active site mutant of Trx1 that represents a catalytic mixed disulfide intermediate in the reduction of PR by the redoxins in the dithiol reaction mechanism ²⁹. In this complex, both proteins interact specifically at multiple points (see Fig. 2 C and Fig. 3). Clearly, the degree of conservation of these interacting residues cannot explain the different functionalities

and efficiencies of the redoxins with PR (Fig. 3). The interactions include many backbone-backbone interactions. Specific side chain interactions are rare and my be taken over by other amino acids, for instance in the case of aspartyl 61 of E. c. Trx1 by the aspartyl residue 37 of E. c. Grx1, located one amino acid N-terminally of aspartyl 61 in the structural alignment (Fig. 3). The molecular interactions between Trx and PR also include specific electrostatic interactions at the short sites/corners of the contact surface (see Fig. 2 D). The ε -amino group of lysyl residue 36 of Trx1 specifically interacts with the β -carboxyl group of aspartyl residue 206 of PR and the guanidino group of arginyl residue 73 of Trx1 with the γ -carboxyl groups of glutamyl residues 238 and 243 of PR. In between these two small positive surface patches of *E. coli* Trx1 is a surface area with a neutral to slightly negative electrostatic surface potential (see Fig. 2D, lower row).

Could these specific complementary electrostatic surface potential patches be a common feature of redoxins that react kinetically with PR and different in those that don't? To address this hypothesis, we analyzed the available structures of the redoxins analyzed kinetically, i.e. *E. coli* Grx1 (pdb code: legr) ³¹, Grx2 (1g7o) ³², Grx3 (3grx) ³³, Trx1 (1xob) ³⁴, and NrdH (1h75) ³⁵, bacteriophage T4 Grx (1de2) ³⁶, *A. thaliana* TrxH1 (1xfl) ³⁷, as well as human Grx2 (2fls) and Trx1 (1ert) ³⁸. From these structures, T4 Grx and *E. coli* Grx2 differ the most, since these redoxins contain elongated loops on the interaction surface (T4 Grx, Fig. 4A) or an additional domain that partly covers the contact area (*E. coli* Grx2, Fig. 4B). These features obviously explain their lack of activity with PR. The remaining structures fall into two groups with respect to their electrostatic characteristics (Fig. 5). The first group consists of *E. coli* Grx1 (Fig. 5A) and Trx1 (Fig. 5B), human Trx1 (Fig. 5C), and *A. thaliana* TrxH1 (Fig. 5D). This group is characterized by a neutral to slightly negative contact area, marked by a few small positive patches (Fig. 5A-D, 5th column). And, moreover, a rather prominent negative electric field protruding into the surrounding solvent outside the contact surface characterized above (Fig. 6A-G). The second group includes *E. coli* Grx3 (Fig. 5E, Fig. 6I), human Grx2 (Fig. 5F, Fig. 6H), and *E. coli* NrdH (Fig. 5G, Fig. 6J). This group lacks

prominent electric fields reaching into the solvent and displays a pronounced positive surface potential in the area corresponding to the contact surface between *E. coli* Trx1 and PR (Fig. 2C-D). Astonishingly, these two groups exactly correspond to the redoxins active with PR (first group) and the redoxins inactive with PR (second group). In fact, the strength and extend of the negative electric field of the redoxins outside the contact area directly correlates to the catalytic efficiency of PR with these redoxins as electron donors (Fig. 6).

Discussion

The specificity of distinct Trx and Grx proteins for any given catalytic or allosteric disulfide, see ⁵, is a key element for the controlled flow of metabolites and the operation of thiol switches in redox signalling ³⁹. Using *E. coli* PR as model, our study suggests that geometric and electrostatic complementary as well as electric fields and thus long-distance electrostatic interactions between the redoxin and their target protein are the key elements for Trx family proteins' specificity and efficiency.

The differences in standard redox potentials between two redox pairs, such as a Trx (red/ox) and a metabolic enzyme such as PR (red/ox), is a measure of the free energy of the reaction and thus how thermodynamically favorable this reaction is. Thermodynamics, however, do not determine physiological reactions. Rate constants are determined by, most of all, the magnitude of the activation energy barrier. This is what enzymes facilitate – increasing reaction rates by lowering activation energies. *In vivo*, the flow of metabolites is controlled by metabolite concentrations, enzymes' specificities, the regulation of enzyme activity, and compartmentalization. As long as a reaction is thermodynamically favorable (or made favorable by, for instance, detracting a reaction product) reaction rates are controlled by proteins. This was nicely confirmed here. The differences in redox potentials of the redoxins and PR did not correlate to the efficiency of the enzyme with these redoxins as electron donors. Similar conclusions were drawn before. The standard redox potential of Trx1 and Grx1 are -270 mV ⁴⁰ and -233 mV ³⁰, respectively, making the Trx the

thermodynamically more favorable reductant. *E. coli* ribonucleotide reductase, however, is catalytically more efficient with Grx1 as electron donor ⁴¹. Moreover, the redoxins which are able or unable to reduce ribonucleotide reductase correspond to the same two groups as the redoxins investigated as reductants for PR here. *E. coli* Trxs 1, Trx2, and Grx1 as well as poplar Grx are able to reduce *E. coli* ribonucleotide reductase ⁸ ⁴² ⁹ ²⁵, whereas *E. coli* Grx2, Grx4, and NrdH display no or only marginal activity ⁴³ ⁴⁴ ²².

The importance for geometric and electrostatic complementary surfaces has been highlighted before in a study that aimed at the determination of the structure of the peroxiredoxin-glutaredoxin (Prx-Grx) hybrid protein from *Haemophilus influenza* 45. This study revealed two interaction sites on the surface of the Prx domain, depending on the reaction cycle of the peroxidase that involves a conformational change of the active site peroxidatic cysteinyl residue. These areas interact with essentially the same contact surface on the Grx domain of a second hybrid protein in the homo tetrameric quaternary structure. Both modes of interaction involve specific electrostatic interactions of two small positive patches on the Grx domain defined by lysyl residue 177 and arginyl residue 212, with two negative patches on the Prx domain, defined by glutamyl 59 and aspartyl-glutamyl residues 89-90 or aspartyl residues 148, 154, and 156 45. This interaction is quite similar to the interaction of Trx1 with PR, see Fig. 2D. Another example for the importance of complementary surfaces was provided by the crystal structures of the two barley TrxH isoforms 1 and 2 and a complex of TrxH2 with the α-amylase/subtilisin inhibitor BASI 46. This study also concluded that substrate specificity and reaction efficiency may be mainly based on complementary contact areas and specific molecular interactions between the Trxs and their target, and not on differences in redox potentials, that are almost identical for these two Trxs ⁴⁷.

Our conclusions are further supported by an analysis of the three more complexes between Trx family proteins and their targets that are available in the protein data base. The complexes of human Trx1 and thioredoxin interacting protein (TXNIP) 48, barely TrxH2 and BASI, and between yeast

Trx1 and methionine sulfoxide reductase A (MsrA) ⁴⁹ are depicted in Fig. 7. The proteins do not only demonstrate surface complementarity, but, when separated, also a perfect complementarity between their electrostatic field maps when the interacting surfaces face each other (Fig. 7, first column).

Long-range electrostatic interactions are thought to be a driving force for facilitating and enhancing the rate of specific binding of a protein to a target 50 51. Not surprisingly, the best studied mechanisms of signalling and regulation – reversible phosphorylation – primarily effect electrostatic interactions. Here, we have seen a strong correlation between the efficiency of PR with various Trx and Grx proteins as electron donor and the extend and strength of the negative electric fields of the redoxins protruding into the solvent, mostly outside the immediate contact area (Fig. 5). The only study addressing this point so far by Bunik et al. 52 analyzed the activation of α -ketoglutarate dehydrogenase by various Trxs. Supporting the conclusions drawn here, this study identified that the length of the α -helix 1 (where part of the active site is located) and the surrounding charges correlate with the influence of the Trxs on the α -ketoglutarate dehydrogenase complex. The efficiency of the Trxs tested directly correlated to the strength of the, in this case positive, electric fields / polarization and the highest dipole vector. Bunik et al. concluded that the 'selective action of a thioredoxin should stem from specific recognition upon formation of the thioredoxin-target complex [...] before the highly reactive catalytic groups are brought together 52. This hypothesis is fully supported by our study. Astonishingly, for these long range electrostatic interactions, amino acid residues outside the contact area can be as or even more important than the residues forming the complementary contact surfaces.

The importance of cellular redox potentials for efficient electron transfer, catalytic or in signalling events, are questionable ⁵³ ⁵⁴. The results and analyses presented here using PR, the substrate tested for the greatest variety of redoxins, suggest that both short- and long-range electrostatic interactions are the major determinants of the specificity of Trx family proteins.

Additional limits are set by the necessity for geometric complementarity. Supported by previous studies and all available structures of Trx-target complexes, this could be the major mechanisms for the target specificity of Trxs and Grxs.

Experimental

General Methods - Chemicals and enzymes were purchased from Sigma-Aldrich (St. Louis MO, USA), unless otherwise stated, and of analytical grade or better. Electrophoresis and Western blotting were run as described in ¹⁶.

Cloning - *E. coli* Grx1 was cloned as a 256 bp *NdeI/Xho*I PCR-fragment from genomic DNA using the oligonucleotides 5'-CACACA<u>CATATG</u>CAAACCGTTATTTTTGGTCG-3' and 5'-CACACA<u>CTCGAG</u>GGCGTCCAGATTTTCTTTCACCC-3' and cloned into vector pET16b.

Protein Expression and Purification - PR was expressed and purified from a pET16b derivative as described in ¹⁶, likewise Grx1. 40 mg of PR and 75 mg Grx1 were obtained per liter LB broth at a purity of > 98 % as judged by SDS-PAGE. Human Grx2 was produced as described in ⁵⁵. Human Trx1, *E. coli* NrdH, and T4 Grx were a kind gift by Arne Holmgren (Karolinska Institutet Stockholm). Recombinant plant thioredoxins were a kind gift by Yves Meyer (Perpignan, France) and Jean-Pierre Jacquot (Nancy, France).

PAPS reductase assay -Activity of PR was measured as acid labile ³⁵[S]-SO₃²⁻ formation from ³⁵[S]-PAPS ¹⁸. ³⁵[S]-PAPS was prepared enzymatically from ³⁵[S]-SO₄²⁻ (Amersham-Buchler, Braunschweig) as described in ¹⁶ using recombinant APS kinase from *Arabidopsis thaliana* ⁵⁶. Kinetic constants were calculated from a series of measurements repeated independently at least three times. The assay mixture (100 μl) contained 100-250 ng·ml⁻¹ of purified PAPS-reductase, 100 mM Tris/HCl pH 8.0, 10 mM Na₂SO₃, 100 μM ³⁵[S]-PAPS (specific radioactivity: 4.2 kBq·nmol⁻¹), 0.5-50 μM redoxin. The redoxins were kept reduced by 10-25 mM dithiothreitol (DTT) and/or 10 mM reduced glutathione.

Spectroscopic methods - We used a double beam spectrophotometer (Sigma ZWS-II, Berlin) for UV-absorbance difference spectroscopy [19] fitted with two sets of tandem cuvettes. Oxidized PR (5 - 50 μ M) and redox buffer in separate compartments of the tandem cuvettes was measured against PR plus redox buffer in the same compartment. The reactants were allowed to equilibrate in

stoppered cuvettes at ambient temperature until the reading of the absorbance difference was constant. The spectral bandwidth was adjusted to 1 nm with Grx1 as reductant and 2 nm for the PR-GrxC14S complex. The scanning speed was 2 nm s⁻¹. The measured absorbance difference was converted into molar absorption changes $\Delta \epsilon$ based on the concentration of PR used. The standard redox potential of PR was determined using glutathione (10 - 100 mM) redox buffers containing a catalytical amount (1:100 in relation to PR, i.e. 0.05-0.5 µM) of E. coli Grx1 at 25°C in 100 mM potassium phosphate pH 7.0. Before use, PAPS-reductase was converted to the fully oxidized state (PR_{ox}) by incubating the protein with PAPS at 25°C for 1 h in the absence of reductants. PAPS, PAP, and sulfite were removed by gel filtration using SephadexG25 (Pharmacia). The enzyme was concentrated using Centriprep concentrators YM3 (Millipore). The samples were placed in the photometer as described above and the change in absorbance was followed continously at 294 nm versus PR_{ox} until equilibrium was reached, i.e. up to seven hours. The ratio of reduced to oxidized PAPS-reductase was obtained by normalizing $\Delta \varepsilon$ to $\Delta \varepsilon_{max}$. The equilibrium constant k_{eq} for the thiol disulfide exchange reaction via glutaredoxin involves only the oxidized and reduced forms of PR and glutathione. Given the standard redox potential of GSH as -240 mV ³⁰, the results were fitted by non linear regression using the Nernst equation with E⁰¹ and n (the number of electrons) as variable parameters.

Computational methods - Protein structures and secondary structure assignments were obtained from the Protein Data Bank (RCBS, http://www.rcsb.org/pdb/home/home.do). Molecular surfaces, contact surfaces and electrostatics were visualized using the Swiss PDB Viewer ⁵⁷ and rendered using the 'Persistance of Vision Raytracer' (Povray, http://www.povray.org/). Detailed molecular interactions were analyzed with 'contact' of the CCP4 suite ⁵⁸. Structural alignments between all redoxins analysed and *E. coli* Trx1 were calculated using the PyMOL Molecular Graphics System, Version 1.7.4 Schrödinger, LLC (http://www.pymol.org/). Electrostatic potential maps were calculated using the Swiss PDB Viewer. The dielectric constant of the solvent and proteins were set

to 78.54 and 4, respectively, for computation applying the Poisson-Boltzmann method. When mapped to the surfaces, electrostatic maps were depicted from -4 (red) to +4 kT/e (blue). The structures of *A. thaliana* Trxs H2 and H3 (template for both: PDB accession 1wmj), as well as *E. coli* Trx2 (template: 3p2a) were modelled using the Swiss-Model server ⁵⁹. Grace (http://plasma-gate.weizmann.ac.il/Grace/) was used for data plotting and regression analysis, Inkscape (http://inkscape.org/) and the 'GNU Image Manipulation Program' (GIMP, http://www.gimp.org/) for preparing the figures.

Conclusions

The rationale for substrate specificity of the proteins from the thioredoxin family is key to the understanding of redox signalling in physiology and pathology. From this work, we conclude that the recognition of disulfide substrates by thioredoxins and glutaredoxins is not determined by redox potentials, but by specific long-distance electrostatic interactions and complementary contact surfaces.

Acknowledgements

The Authors wish to thank Arne Holmgren (Stockholm, Sweden), Jean-Pierre Jacquot (Nancy, France), and Yves Meyer (Perpignan, France) for providing proteins for analyses. We express our gratitude to Marcel Deponte (Heidelberg, Germany) for discussing the manuscript and inspiring this work. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Li 984/3-1 and Be 3259/5-1).

References

- 1 C. H. Lillig and A. Holmgren, *Antioxid. Redox Signal.*, 2007, **9**, 25–47.
- 2 M. M. Gallogly and J. J. Mieyal, Curr. Opin. Pharmacol., 2007, 7, 381–91.
- 3 C. H. Lillig, C. Berndt and A. Holmgren, *Biochim. Biophys. Acta BBA Gen. Subj.*, 2008, **1780**, 1304–1317.
- 4 E.-M. Hanschmann, J. R. Godoy, C. Berndt, C. Hudemann and C. H. Lillig, *Antioxid. Redox Signal.*, 2013, **19**, 1539–1605.
- 5 B. Schmidt, L. Ho and P. J. Hogg, *Biochemistry (Mosc.)*, 2006, **45**, 7429–7433.
- 6 J. L. Martin, Struct. Lond. Engl. 1993, 1995, 3, 245-50.
- 7 Y. Qi and N. V. Grishin, *Proteins*, 2005, **58**, 376–388.
- 8 T. C. Laurent, E. C. Moore and P. Reichard, J. Biol. Chem., 1964, 239, 3436–44.
- 9 A. Holmgren, J. Biol. Chem., 1979, **254**, 3664–71.
- 10 P. Gonzalez Porqué, A. Baldesten and P. Reichard, J. Biol. Chem., 1970, 245, 2371-2374.
- 11 M. L. Tsang and J. A. Schiff, *J. Bacteriol.*, 1978, **134**, 131–138.
- 12 M. L. Tsang, J. Bacteriol., 1981, 146, 1059–1066.
- 13 F. A. Krone, G. Westphal and J. D. Schwenn, *Mol. Gen. Genet. MGG*, 1991, **225**, 314–319.
- 14 J. D. Schwenn, F. A. Krone and K. Husmann, Arch. Microbiol., 1988, 150, 313–319.
- 15 U. Berendt, T. Haverkamp, A. Prior and J. D. Schwenn, Eur. J. Biochem. FEBS, 1995, 233, 347–356.
- 16 C. H. Lillig, A. Prior, J. D. Schwenn, F. Aslund, D. Ritz, A. Vlamis-Gardikas and A. Holmgren, *J Biol Chem*, 1999, **274**, 7695–7698.
- 17 C. H. Lillig, A. Potamitou, J.-D. Schwenn, A. Vlamis-Gardikas and A. Holmgren, *J Biol Chem*, 2003, **278**, 22325–22330.
- 18 J. D. Schwenn and U. Schriek, Z. Für Naturforschung C.J. Biosci., 1987, 42, 93–102.
- 19 F. Aslund, B. Ehn, A. Miranda-Vizuete, C. Pueyo and A. Holmgren, *Proc. Natl. Acad. Sci. U. S. A.*, 1994, **91**, 9813–9817.
- 20 M. Russel, P. Model and A. Holmgren, J. Bacteriol., 1990, 172, 1923–1929.
- 21 A. P. Fernandes, M. Fladvad, C. Berndt, C. Andresen, C. H. Lillig, P. Neubauer, M. Sunnerhagen, A. Holmgren and A. Vlamis-Gardikas, *J Biol Chem*, 2005, **280**, 24544–24552.
- 22 A. Jordan, F. Aslund, E. Pontis, P. Reichard and A. Holmgren, J. Biol. Chem., 1997, 272, 18044–18050.
- 23 O. Berglund and B. M. Sjöberg, J. Biol. Chem., 1970, 245, 6030–6035.
- 24 Y. Meyer, J. P. Reichheld and F. Vignols, *Photosynth. Res.*, 2005, **86**, 419–433.
- 25 N. Rouhier, A. Vlamis-Gardikas, C. H. Lillig, C. Berndt, J.-D. Schwenn, A. Holmgren and J.-P. Jacquot, *Antioxid. Redox Signal.*, 2003, **5**, 15–22.
- 26 Y. Tagaya, Y. Maeda, A. Mitsui, N. Kondo, H. Matsui, J. Hamuro, N. Brown, K. Arai, T. Yokota and H. Wakasugi, *EMBO J.*, 1989, **8**, 757–764.
- 27 M. Lundberg, C. Johansson, J. Chandra, M. Enoksson, G. Jacobsson, J. Ljung, M. Johansson and A. Holmgren, *J. Biol. Chem.*, 2001, **276**, 26269–75.
- 28 V. N. Gladyshev, A. Liu, S. V. Novoselov, K. Krysan, Q. A. Sun, V. M. Kryukov, G. V. Kryukov and M. F. Lou, *J. Biol. Chem.*, 2001, **276**, 30374–80.
- 29 J. Chartron, C. Shiau, C. D. Stout and K. S. Carroll, *Biochemistry (Mosc.)*, 2007, **46**, 3942–3951.
- 30 F. Aslund, K. D. Berndt and A. Holmgren, J. Biol. Chem., 1997, 272, 30780–6.
- 31 P. Sodano, T. H. Xia, J. H. Bushweller, O. Björnberg, A. Holmgren, M. Billeter and K. Wüthrich, *J. Mol. Biol.*, 1991, **221**, 1311–1324.
- 32 B. Xia, A. Vlamis-Gardikas, A. Holmgren, P. E. Wright and H. J. Dyson, *J. Mol. Biol.*, 2001, **310**, 907–918.
- 33 K. Nordstrand, F. slund, A. Holmgren, G. Otting and K. D. Berndt, J. Mol. Biol., 1999, 286, 541–552.
- 34 M. F. Jeng, A. P. Campbell, T. Begley, A. Holmgren, D. A. Case, P. E. Wright and H. J. Dyson, *Struct. Lond. Engl. 1993*, 1994, **2**, 853–868.
- 35 M. Stehr, G. Schneider, F. Aslund, A. Holmgren and Y. Lindqvist, *J. Biol. Chem.*, 2001, **276**, 35836–35841.
- 36 Y. Wang, G. Amegbey and D. S. Wishart, *J. Biomol. NMR*, 2004, **29**, 85–90.
- 37 F. C. Peterson, B. L. Lytle, S. Sampath, D. Vinarov, E. Tyler, M. Shahan, J. L. Markley and B. F. Volkman, *Protein Sci. Publ. Protein Soc.*, 2005, **14**, 2195–2200.
- 38 A. Weichsel, J. R. Gasdaska, G. Powis and W. R. Montfort, Struct. Lond. Engl. 1993, 1996, 4, 735–751.

- 39 M. Deponte and C. H. Lillig, *Biol. Chem.*, 2015.
- 40 G. Krause, J. Lundström, J. L. Barea, C. Pueyo de la Cuesta and A. Holmgren, *J. Biol. Chem.*, 1991, **266**, 9494–9500.
- 41 A. P. Fernandes and A. Holmgren, *Antioxid. Redox Signal.*, 2004, **6**, 63–74.
- 42 A. Miranda-Vizuete, A. E. Damdimopoulos, J. Gustafsson and G. Spyrou, *J. Biol. Chem.*, 1997, **272**, 30841–30847.
- 43 A. Vlamis-Gardikas, F. Aslund, G. Spyrou, T. Bergman and A. Holmgren, *J. Biol. Chem.*, 1997, **272**, 11236–11243.
- 44 R. Ortenberg, S. Gon, A. Porat and J. Beckwith, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 7439–7444.
- 45 S. J. Kim, J. R. Woo, Y. S. Hwang, D. G. Jeong, D. H. Shin, K. Kim and S. E. Ryu, *J. Biol. Chem.*, 2003, **278**, 10790–10798.
- 46 K. Maeda, P. Hägglund, C. Finnie, B. Svensson and A. Henriksen, *Protein Sci. Publ. Protein Soc.*, 2008, 17, 1015–1024.
- 47 K. Maeda, P. Hägglund, O. Björnberg, J. R. Winther and B. Svensson, FEBS Lett., 2010, 584, 3376–3380.
- 48 J. Hwang, H.-W. Suh, Y. H. Jeon, E. Hwang, L. T. Nguyen, J. Yeom, S.-G. Lee, C. Lee, K. J. Kim, B. S. Kang, J.-O. Jeong, T.-K. Oh, I. Choi, J.-O. Lee and M. H. Kim, *Nat. Commun.*, 2014, **5**, 2958.
- 49 X.-X. Ma, P.-C. Guo, W.-W. Shi, M. Luo, X.-F. Tan, Y. Chen and C.-Z. Zhou, *J. Biol. Chem.*, 2011, **286**, 13430–13437.
- 50 M. K. Gilson, Curr. Opin. Struct. Biol., 1995, 5, 216–223.
- 51 H.-X. Zhou, *Phys. Biol.*, 2005, **2**, R1–25.
- 52 V. Bunik, G. Raddatz, S. Lemaire, Y. Meyer, J. P. Jacquot and H. Bisswanger, *Protein Sci. Publ. Protein Soc.*, 1999, **8**, 65–74.
- 53 L. Flohé, *Biochim. Biophys. Acta*, 2013, **1830**, 3139–3142.
- 54 C. Berndt, C. H. Lillig and L. Flohé, Front. Pharmacol., 2014, 5.
- 55 C. H. Lillig, C. Berndt, O. Vergnolle, M. E. Lonn, C. Hudemann, E. Bill and A. Holmgren, *Proc. Natl. Acad. Sci.*, 2005, **102**, 8168–8173.
- 56 C. H. Lillig, S. Schiffmann, C. Berndt, A. Berken, R. Tischka and J. D. Schwenn, *Arch. Biochem. Biophys.*, 2001, **392**, 303–310.
- 57 N. Guex and M. C. Peitsch, *Electrophoresis*, 1997, 18, 2714–2723.
- 58 M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin and K. S. Wilson, *Acta Crystallogr. Sect. D*, 2011, **67**, 235–242.
- 59 T. Schwede, J. Kopp, N. Guex and M. C. Peitsch, *Nucleic Acids Res.*, 2003, **31**, 3381–3385.
- 60 H. El Hajjaji, M. Dumoulin, A. Matagne, D. Colau, G. Roos, J. Messens and J.-F. Collet, *J. Mol. Biol.*, 2009, **386**, 60–71.
- 61 W. H. Watson, J. Pohl, W. R. Montfort, O. Stuchlik, M. S. Reed, G. Powis and D. P. Jones, *J. Biol. Chem.*, 2003, **278**, 33408–33415.
- 62 J. Sagemark, T. H. Elgán, T. R. Bürglin, C. Johansson, A. Holmgren and K. D. Berndt, *Proteins*, 2007, **68**, 879–92.

Figure legends

Figure 1 – Determination of the redox potential of PAPS reductase. (A) Difference spectrum of oxidized (reference) versus reduced PR, (A-1) the fully reduced enzyme, (A-2) at a redox potential – defined by glutathione redox buffer – of -100 mV. (B). The differences in absorption at 294 nm were used to calculate the reduced/oxidized ratio of PR after incubation of the enzyme in various redox buffers until equilibrium was reached, i.e. up to seven hours. The 25 individual measurements were fitted to the Nernst equation (solid line) yielding a standard redox potential of PR of -162 mV. For experimental details, see Experimental Procedures.

Figure 2 – Structure of the E. coli PAPS reductase-mutant Trx1 mixed disulfide complex.

(A) Secondary structure representation of the complex, top: PR (CysH), bottom: Trx1. (B) Surfaces in atomic type coloring after rotation of PR by 90° backwards and Trx1 by 90° to the front. The arrow points to the two cysteinyl sulfur atoms that form the intermediate mixed disulfide. (C) The contact surfaces marked in blue. (D) The electrostatic surface potentials (from red = -4 to blue = +4 kT/e, using atomic partial charges) mapped to the surface and highlighting the contact surfaces and some specifically interacting amino acid site chains. All pictures and data were computed using the DeepView / Swiss-PDB Viewer 4.1 with PDB accession number $208v^{29}$.

Figure 3 – Structural alignment of the thioredoxin family proteins investigated in this study. The structures of the various redoxins were pairwise aligned to the structure of E. coli Trx 1 (PDB code 1xob) using PyMOL and thereafter manually arranged in this alignment. The residues directly interacting in the E. c. Trx1-PAPS reductase complex were highlighted with a green background. The residues were also specified below the sequence, as well as the interacting residues in PAPS reductase and the parts of the amino acids involved in these interactions (bb: backbone, sc: side chain). The interactions were calculated with 'contact' of the CCP4 suite (58). Conserved residues were highlighted with a yellow, positively charged residues with a blue, and negatively charged residues with a red background. The positions of the active site as well as the Trx-fold

specific cis-Pro residues were also marked above the sequences. The secondary structures of E.c. Grx1 was also included above the sequences, the secondary structure of E. c. Trx1 below the sequences.

Figure 4 – Structures of Grxs non-functional with PAPS reductase with altered active site geometry. Secondary structure representations of (A) T4 Grx and (B) *E. coli* Grx2. The loops and domain protruding from the area corresponding to the contact surface in Trx1 are marked. The pictures were computed using the DeepView / Swiss-PDB Viewer 4.1 with PDB accession numbers 1de2 (T4) ³⁶ and 1g7o (Grx2) ³².

Figure 5 – Structural analysis of some of the Trxs and Grxs tested as electron donor for PAPS reductase. First column: Secondary structure representation from the front, second column: secondary structure representation from the top, i.e. rotated by 90° to the front. Third column: Surface representation of the active site and potential contact areas in atomic type coloring. Fourth column: Electrostatic surface potentials (from red = -4 to blue = +4 kT/e, using atomic partial charges) mapped to the surface. The pictures were computed using the DeepView / Swiss-PDB Viewer 4.1 with PDB accession numbers: (A) *E. coli* Grx1 (1egr) ³¹, (B) *E. coli* Trx1 (1xob) ³⁴, (C) human Trx1 (1ert) ³⁸, (D) *A. thaliana* TrxH1 (1xfl) ³⁷, (E) *E. coli* Grx3 (3grx) ³³, (F) human Grx2 (2fls), and (G) *E. coli* NrdH (1h75) ³⁵.

PAPS reductase. The figures show the secondary structure representations (in front view, see Fig. 4, first column) with the computed electric fields protruding into the surrounding solvent. Additionally, the efficiency of PR with the various redoxins as electron donor were included. The electrostatic potential maps (from red = -4 to blue = +4 kT/e, using atomic partial charges) and the pictures were computed using the DeepView / Swiss-PDB Viewer 4.1. The structures marked with an asterisk were not experimentally determined but computed here by molecular modelling using the Swiss-model server. (A) *A. thaliana* TrxH3* (modelled with template 1wmj), (B) *E. coli* Trx1

(1xob), (C) *E. coli* Grx1 (1egr), (D) human Trx1 (1ert), (E) *A. thaliana* TrxH4*(modelled with template 1wmj), (F) *E. coli* Trx2* (modelled with template 3p2a), (G) *A. thaliana* TrxH1 (1xfl), (H) human Grx2 (2fls), (I) *E. coli* Grx3 (3grx), and *E. coli* NrdH (1h75).

Figure 7 – **Interaction analysis of other Trx-target protein complexes from the protein data bank.** A ribbon representation of the complexes is shown in the second column. The atomic, interacting and electrostatic surfaces are shown in columns three to five, arranged as in figure 2. The first column features the electrostatic maps of the interacting proteins separated from each other. A crude representation of the surface charges was added to highlight the complementarity of the electrostatic fields of the proteins pointing to each other with their interacting surfaces. (A)

Complex between human Trx1 and the thioredoxin interacting protein (TXNIP), pdb code 4ll4. (B)

Complex between Hordeum vulgare (barley) TrxH2 and BASI, pdb code 2iwt. (C) Complex between yeast Trx1 and methionine sulfoxide reductase A (MsrA), pdb code 3pin.

Table 1 - Redox potentials and kinetic parameters of various thioredoxins and glutaredoxins

(A.t.: Arabidopsis thaliana, E.c.: Escherichia coli, H.s.: Homo sapiens, n.a.: not availabale; p.s.: present study)

redoxin		redoxpote	ential	kinetic parameters with PR				
abbr.	source	$\Delta \mathrm{E}^{0'}$	ref.	K_m	V_{max}	$k_{cat}\cdot K_m^{-1}$		ref.
		mV		μ <i>M</i>	$U \cdot mg^{-1}$	%		
Trx1	E.c.	-270	40	13.7	6.7	100	16	
Trx2	E.c.	-221	60	34.2	6.3	38	16	
Grx1	E.c.	-233	30	14.9	5.1	70	16	
Grx2	E.c.	(n.a.)			no activity		16	
Grx3	E.c.	-198	30		no activity		16	
Grx4	E.c.	(n.a.)			no activity			p.s.
NrdH	E.c.	-248.5	22		no activity			p.s.
Grx	T4	-240	23		no activity			p.s.
TrxH1	A.t.	(n.a.)		59.0	5.3	18		p.s.
TrxH2	A.t.	(n.a.)		43.1	4.7	23		p.s.
TrxH3	A.t.	(n.a.)		17.8	13.2	154		p.s.
TrxH4	A.t.	(n.a.)		26.1	5.7	45		p.s.
Grx	poplar	(n.a.)		63.7	10.4	33	25	
hTrx1	H.s.	-230	61	68.1	19.6	59		p.s.
hGrx2	H.s.	-221	62		no activity			p.s.



Figure 2	2
----------	---

24 / 29

